Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He has over 30+ years of experience in Life Sciences. He is also a Life Sciences industry advisor at MIT, his alma mater. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC. Mr. Anbil has consulted with and counseled Health and Life Sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He is a diplomat/fellow at MIT CSAIL. He is a healthcare expert member of the World Economic Forum (WEF). He was a member of the IBM Industry Academy, a very selective group of professionals inducted into the academy by invitation only, the highest honor at IBM.

Partha S. Anbil

A comprehensive comparative evaluation of three primary clinical data management architectures

As healthcare organizations transition toward data-driven paradigms, the volume and variety of datasets, ranging from electronic health records (EHRs) and genomic sequencing to wearable sensor streams and high-resolution radiology images, have grown exponentially.

 The global volume of healthcare data was estimated to reach 2,314 exabytes by 2020, and this trajectory has only accelerated with the adoption of Internet of Things (IoT) devices and remote patient monitoring platforms.

 The successful deployment of AI applications in clinical settings hinges critically on the underlying data management architecture. AI models require high-quality, bias-controlled, and representative training data to avoid the well-known “garbage in, garbage out” phenomenon. Furthermore, transparency through provenance tracking and versioning, standards-based interoperability for seamless data exchange, and the ability to handle large, multimodal datasets are non-negotiable prerequisites for any organization serious about clinical AI.

To evaluate the efficacy of data management solutions in this demanding context, industry standards increasingly rely on two complementary frameworks. The FAIR principles ensure that data is findable through unique persistent identifiers, accessible via standard communication protocols, interoperable through machine-readable formats and standardized vocabularies such as SNOMED-CT and LOINC, and reusable with clear licensing and domain-specific metadata.

 The 5 V’s of Big Data address the technical challenges of managing large-scale clinical datasets: 

Volume (the sheer size of EHR, genomic, and imaging data) 

Variety (the heterogeneity of structured, semi-structured, and unstructured formats) 

Velocity (the need for both batch and real-time processing)

Veracity (data quality, integrity, and traceability)

Value (the ability to extract actionable insights for research and patient care). 

Adopting this combined FAIR-5V perspective enables healthcare institutions to build future-proof infrastructures that support both clinical operations and AI research.

The Three Pillars of Clinical Data Architecture

Clinical Data Warehouses: The Bastion of Governance

The Clinical Data Warehouse (cDWH) has been the established standard in healthcare data management for decades. Designed as a central data hub, it harmonizes data from various clinical sources, enforces interoperability standards, and organizes patient data into highly structured, tabular formats using a “schema-on-write” approach. A defining characteristic of cDWHs is their adherence to atomicity, consistency, isolation, and durability (ACID) properties, which ensures that every transaction is dependable, and data integrity is maintained even in the event of system failures. Atomicity guarantees all-or-nothing execution, consistency ensures data remains valid before and after transactions, isolation prevents concurrent transactions from interfering with each other, and durability ensures committed data persists permanently.

These properties make cDWHs exceptionally well-suited for environments requiring strict regulatory compliance, reliable structured analysis, and straightforward auditing.

 They provide a stable foundation for training robust machine learning models on clean, well-cataloged tabular data, and are particularly valuable for hospital governance, long-term trend analyses, and business intelligence dashboards. However, cDWHs face significant challenges in the modern AI landscape. The rapid influx of unstructured data, such as radiology images, clinical notes, and waveform recordings, makes it increasingly difficult to maintain the rigid, fixed schema approach. Every new data element requires ETL (Extract, Transform, Load) reengineering, and scaling up to accommodate images, notes, or real-time feeds is both costly and slow. Furthermore, the batch-oriented processing model of cDWHs can delay the detection of acute clinical events, limiting their utility for time-critical medical decision-making.

Clinical Data Lakes (cDL): Flexibility and Scale

To address the limitations of cDWHs, the Clinical Data Lake (cDL) emerged as an architectural approach that enables the storage of vast amounts of raw data in its original format, whether structured EHR records, semi-structured HL7 or FHIR messages, or unstructured radiology images and clinical notes. Unlike cDWHs, cDLs utilize a “schema-on-read” approach, allowing organizations to ingest and store data without defining a schema upfront.

 This provides exceptional scalability and flexibility, enabling multimodal patient views and supporting near real-time data processing through distributed file systems and big data frameworks such as Hadoop and Spark.

cDLs are highly cost-effective for storing petabytes of diverse data and are well-suited for exploratory research, machine learning prototyping, IoT and streaming data analysis, and future-proofing data assets for emerging analytic methods. However, this flexibility comes at a significant governance cost. Without disciplined metadata management and robust data governance policies, a cDL can quickly degrade into a “data swamp,” a repository where data becomes unfindable, unreliable, and ultimately unusable. The absence of built-in enforcement for data types or business rules means that imputation logic and provenance tracking must be manually recoded for every study, posing challenges for maintaining data quality and veracity across large-scale research programs.

Clinical Data Lakehouses (cDLH): The Hybrid Frontier

The Clinical Data Lakehouse (cDLH) represents a newer, more complex hybrid approach that seeks to combine the scalable storage capabilities of a cDL with the structured queries, performance optimizations, and ACID transaction guarantees of a cDWH. First conceptualized by Zaharia et al. (2021), the lakehouse architecture applies open data formats and comprehensive data management techniques to provide a unified platform where raw data can be stored cost-effectively and processed in structured formats as required. In the clinical context, cDLHs combine a lake-style raw data landing zone with warehouse-style Delta or ACID tables and a single metastore that tracks both processed and unprocessed assets.

cDLHs offer the most comprehensive capabilities among the three architectures, supporting both real-time data ingestion and structured querying within a single platform. They are ideal for large, research-intensive institutions that need to integrate classic tabular data with vast amounts of unstructured research data such as images and omics data, enabling both standard reporting and advanced AI applications on the same dataset. However, cDLHs are extraordinarily complex, often cloud-native, and require interdisciplinary expertise spanning traditional data warehousing principles, modern big data methods (distributed systems, streaming), and DevOps practices including Docker, Kubernetes, and identity management. The initial setup and ongoing maintenance demand significant resources, posing a particular challenge for organizations with limited technical capacity.

Comparative Evaluation Across the 5 Vs of Big Data

To systematically assess these architectures, this article evaluates them against the 5 V’s of Big Data using an illustrative scoring framework derived from the qualitative findings of Gebler et al. (2025).

 As shown in the radar chart below, cDWHs score highly on Veracity, reflecting their strict schema enforcement and ACID compliance, but lag significantly in Variety (limited to structured formats) and Velocity (batch-oriented processing). Conversely, cDLs excel in Volume and Variety due to their schema-on-read flexibility and distributed storage, but struggle with Veracity owing to weaker governance controls. The cDLH architecture achieves consistently high scores across all five dimensions, reflecting its hybrid design that balances governance with flexibility, though at the cost of greater implementation complexity.

Navigating Complexity: Implementation, Maintenance, and Expertise

Beyond technical performance across the 5 V’s, healthcare executives and technical leaders must carefully weigh the operational trade-offs associated with each architecture. Gebler et al. identify four critical dimensions of complexity: implementation effort, maintenance and scalability, required technical expertise, and coordination complexity.

: cDWHs require detailed data models, extensive ETL development, and a stable database system, typically following a fixed project plan with defined phases for schema design, ETL development, testing, and go-live. Although the initial effort is high, the resulting structure is clear and stable for consistent data management. cDLs benefit from a schema-on-read approach that reduces upfront modeling, but continuous maintenance and expertise in big data technologies such as Hadoop and cloud object storage are essential. cDLHs demand the orchestration of both schema-on-write and schema-on-read functionalities, complex ETL or transform pipelines, robust security concepts, and distributed compute environments, resulting in the highest initial integration and development effort among the three architectures.

: cDWHs require continuous maintenance for schema extensions, data source changes, and performance tuning, with vertical scaling becoming increasingly expensive as data volumes grow. The batch-oriented structure can become a bottleneck for real-time applications. cDLs offer cost-effective horizontal scaling through distributed file systems but require active monitoring, strict data governance, and continuous quality management to prevent data swamp degradation. cDLHs support dynamic scalability for both compute and storage but involve the most complex maintenance regime, as both the lake and warehouse components must be independently managed and synchronized.

: cDWHs rely on well-established skills in relational databases, SQL, and ETL tools. cDLs demand expertise in big data frameworks (Hadoop, Spark), streaming tools (Kafka, Flume), and cloud storage, along with proficiency in analyzing and modeling unstructured data. cDLHs require the broadest range of interdisciplinary expertise, combining traditional data warehousing knowledge with big modern data techniques and cloud-native DevOps practices, a combination that poses a significant staffing challenge for many healthcare organizations.

Strategic Recommendations and Application Scenarios

The optimal data management architecture depends heavily on an organization’s specific needs, available resources, data landscape, and strategic goals. Drawing on the comparative analysis and real-world implementations documented by Gebler, et al., the following scenario-based recommendations are presented.

It is important to note that cost analysis and legacy system integration also play critical roles in architecture selection. While cDWHs may have high upfront costs due to extensive ETL development and schema design, they often offer lower long-term operational costs due to their stable nature.

 cDLs offer cost-effective scalability for large datasets but require ongoing investment in metadata management and system monitoring. cDLHs promise a balance between structure and flexibility but require significant initial integration costs and ongoing maintenance. Healthcare organizations should also consider their existing IT infrastructure: cDWHs generally offer smoother integration with established relational databases and clinical information systems, while cDLs and cDLHs may require additional transformation layers and custom connectors.

Building Resilient, Future-Proof Data Ecosystems

As the healthcare sector continues to embrace AI and advanced analytics, the underlying clinical data infrastructure must evolve to meet increasingly demanding requirements. Clinical Data Warehouses provide the necessary stability, governance, and auditability for structured reporting and regulatory compliance, but they are increasingly constrained by the volume and variety of modern medical data.

 Clinical Data Lakes offer the requisite scale and flexibility for exploratory research and machine learning innovation, but they introduce significant governance risks that can undermine data quality if not carefully managed. The Clinical Data Lakehouse emerges as the most comprehensive solution, bridging the gap between structured reliability and unstructured flexibility while supporting both real-time and batch analytics on a unified platform.

However, the high technical complexity and implementation costs of cDLHs mean they are currently best suited for large, research-intensive institutions with the resources and expertise to manage hybrid environments.

 Future research and development should focus on reducing the complexity of lakehouse implementations, improving the integration of clinical standards such as HL7 FHIR, and developing more accessible tooling that lowers the barrier to entry for smaller organizations. Ultimately, healthcare organizations must align their architectural choices with their immediate analytical needs, long-term scalability goals, and available technical expertise to build resilient, future-proof data ecosystems that serve both clinical operations and the advancing frontier of AI-driven medical research.

Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.

Gebler R, Reinecke I, Sedlmayr M, Goldammer M. 

Enhancing Clinical Data Infrastructure for AI Research: Comparative Evaluation of Data Management Architectures

. J Med Internet Res. 2025;27: e74976. doi:10.2196/74976.

Shilo S, Rossman H, Segal E. Axes of a revolution: challenges and promises of big data in healthcare. 

. 2020;26(1):29-38. doi:10.1038/s41591-019-0727-5.

Baloch L, Bazai SU, Marjan S, Aftab F, Aslam S, Neo T, et al. A review of big data trends and challenges in healthcare. 

. 2023;14(6):1320. doi:10.14716/ijtech. v14i6.6643.

Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. 

. 2016; 3:160018. doi:10.1038/sdata.2016.18.

Pavlenko E, Strech D, Langhof H. Implementation of data access and use procedures in clinical data warehouses: a systematic review of literature and publicly available policies. 

. 2020;20(1):157. doi:10.1186/s12911-020-01177-z.

Sebaa A, Chikh F, Nouicer A, Tari A. Medical big data warehouse: architecture and system design, a case study: improving healthcare resources distribution. 

. 2018;42(4):59. doi:10.1007/s10916-018-0894-9.

El Aissi ME, Benjelloun S, Loukili Y, Lakhrissi Y, El Boushaki AE, Chougrad H, et al. Data lake versus data warehouse architecture: a comparative study. In: 

Proceedings of the 6th International Conference on Wireless Technologies, Embedded, and Intelligent Systems

. 2020. doi:10.1007/978-981-33-6893-4_19.

Quix C, Hai R. Data Lake. In: Sakr S, Zomaya AY, editors. 

Zaharia M, Ghodsi A, Xin R, Armbrust M. Lakehouse: a new generation of open platforms that unify data warehousing and advanced analytics. In: 

Proceedings of the 11th Conference on Innovative Data Systems Research

Harby AA, Zulkernine F. From data warehouse to Lakehouse: a comparative review. In: 

Proceedings of the 2022 IEEE International Conference on Big Data

. 2022. doi:10.1109/BigData55660.2022.10020719.

Nambiar A, Mundra D. An overview of data warehouse and data lake in modern enterprise data management. 

. 2022;6(4):132. doi:10.3390/bdcc6040132.

Bellazzi R. Big data and biomedical informatics: a challenging opportunity. 

. 2014;9(1):8-13. doi:10.15265/IY-2014-0024.

Lee CH, Yoon HJ. Medical big data promises and challenges. 

. 2017;36(1):3-11. doi: 10.23876/j.krcp.2017.36.1.3.

Begoli E, Goethert I, Knight K. A Lakehouse architecture for the management and analysis of heterogeneous data for biomedical research and mega-biobanks. In: 

Proceedings of the 2021 IEEE International Conference on Big Data

. 2021. doi:10.1109/BigData52589.2021.9671534.

Xiao Q, Zheng W, Mao C, Hou W, Lan H, Han D, et al. MHDML: construction of a medical Lakehouse for multi-source heterogeneous data. In: 

Proceedings of the 11th International Conference on Health Information Science

. 2022. doi:10.1007/978-3-031-20627-6_12.

Articles

AI-ready clinical data infrastructures must accommodate rapidly expanding multimodal data while preserving quality, provenance, interoperability, and regulatory-grade governance. Using FAIR principles alongside the 5 V’s of Big Data clarifies architectural trade-offs among clinical data warehouses, lakes, and lakehouses. Warehouses deliver ACID-backed veracity and auditability but struggle with unstructured data and real-time needs. Data lakes scale for volume/variety and exploratory AI, yet risk “data swamps” without strong metadata and governance. Lakehouses unify both paradigms, enabling batch and streaming analytics, but impose substantial complexity, cloud-native tooling demands, and resourcing burdens.

Three primary clinical data management architectures--Clinical Data Warehouses, Clinical Data Lakes, and Clinical Data Lakehouses--are the newest technologies aiming to leverage AI for predictive analytics.

Enhancing Clinical Data Infrastructure for AI Research: A Strategic Guide for Pharma Professionals

Hybrid Cloud Architecture | Created with Canva

Pharmaceutical and biotechnology organizations face an unprecedented dual mandate: Accelerate innovation through advanced data-intensive technologies while maintaining compliance with the world's most stringent regulatory frameworks. Hybrid cloud architecture has emerged as the strategic solution to this challenge, combining the scalability and innovation of the public cloud with the control and security of private infrastructure. With the life sciences cloud computing market capturing its largest share through hybrid deployments in 2024 and projected to maintain this leadership through 2034, this architectural approach has become fundamental to pharmaceutical operations.

This article examines how hybrid cloud architecture enables pharmaceutical companies to navigate the complex landscape of drug discovery, development, manufacturing, and commercialization. We explore the regulatory imperatives of driving hybrid adoption, analyze proven deployment patterns across the pharmaceutical value chain, and demonstrate how leading organizations leverage this model to accelerate time-to-market while ensuring data integrity, intellectual property protection, and regulatory compliance.

How Does the Industry Navigate Complex Regulatory Requirements?

The pharmaceutical industry operates under an intricate web of regulations that creates unique infrastructure challenges. The Food and Drug Administration (FDA)’s 21 

Part 11 governs electronic records and signatures, while Good Practice quality guidelines impose strict requirements for data integrity, auditability, and control across all phases of pharmaceutical production.

The globalization of clinical trials and supply chains further introduces international data sovereignty laws that dictate where and how patient data can be stored and processed.

Recent regulatory developments have intensified these infrastructure requirements. The FDA’s January 2025 draft guidance on AI and Machine Learning in drug development, combined with the joint FDA-European Medicines Agency (EMA) guiding principles released in January 2026, emphasizes model governance, data lineage, and transparency of AI-driven decision-making.

 The joint FDA-EMA framework establishes 10 guiding principles for AI in drug development, including:

Human-centric design with appropriate oversight

Risk-based approaches proportionate to impact

Adherence to quality management and regulatory standards

Clear context of use and limitations documentation

Multidisciplinary expertise in development and deployment

Robust data governance and documentation practices

Rigorous model design and development methodologies

Risk-based performance assessment and validation

Comprehensive life cycle management protocols

Clear essential information for regulatory review

These requirements necessitate infrastructure that offers complete visibility and control—capabilities more readily achieved in hybrid environments than pure public cloud models.

How Can Organizations Use Hybrid Cloud to Protect Their Intellectual Property and Competitive Advantage?

Beyond regulatory compliance, intellectual property protection remains paramount for pharmaceutical organizations. Drug discovery data, clinical trial results, and proprietary manufacturing processes represent billions of dollars in financial and competitive value. While public cloud providers offer sophisticated security, the fundamental architecture—where data resides on infrastructure shared with other tenants—creates concerns that executives and compliance officers find difficult to accept.

Hybrid cloud architectures mitigate these concerns by enabling organizations to retain their most sensitive data within private, single-tenant environments while benefiting from public cloud innovation and scalability. This approach provides the security posture required for board-level confidence while enabling access to innovative computational resources.

What Are the Fundamental Principles of Hybrid Deployment?

Hybrid cloud architectures resolve the inherent tensions between innovation and control by enabling workload segmentation based on risk profiles, regulatory requirements, and computational demands. The fundamental principle is straightforward: Maintain regulated, sensitive data on premises or in private cloud environments while leveraging public cloud resources for computationally intensive, less regulated workloads.

Successful pharmaceutical implementations follow 3 established architectural patterns:

: Organizations classify data into tiers based on regulatory sensitivity. Tier 1 data—clinical trial records and patient information—resides exclusively on premises or in private clouds. Tier 2 data, including preclinical research and computational chemistry results, permits private cloud storage with selective public cloud replication. Tier 3 data, such as published research and public datasets, can freely utilize public cloud resources.

: Rather than moving sensitive data to cloud computing resources, federated learning enables algorithms to travel to the data. This paradigm shift allows pharmaceutical companies to leverage AI and machine learning power while maintaining complete control over proprietary datasets. Analytical models train on distributed data sources without exposing or centralizing sensitive information.

: Life sciences workloads exhibit extreme variability. Genomic sequencing, molecular dynamics simulations, and AI model training create sudden demand spikes that traditional infrastructure cannot economically address. Hybrid architecture enables automatic scaling to public cloud resources during peak demand while maintaining baseline operations on premises, optimizing both cost and performance.

How Does Hybrid Cloud Accelerate Early-Stage Drug Discovery Research?

The drug discovery pipeline is characterized by massive computational demands, making it ideal for a strategic hybrid cloud application. Early-stage activities—high-throughput screening, molecular dynamics simulations, and virtual screening—generate enormous data volumes requiring immense parallel processing power. These workloads suit the elastic, on-demand resources of public cloud, allowing research teams to accelerate discovery timelines without massive upfront capital investment in on-premises hardware.

The partnership between Lilly and NVIDIA exemplifies this strategy in action. In October 2025, the companies announced a collaboration to build the pharmaceutical industry's "most powerful" AI supercomputer and AI factory, featuring more than 1000 NVIDIA Blackwell Ultra GPUs.

 This on-premises infrastructure handles Lilly's most sensitive proprietary molecular modeling and structure-activity relationship analysis. Simultaneously, the company leverages Amazon Web Services’ elastic computing resources to process high-volume computational chemistry workflows during peak demand. This hybrid approach has dramatically reduced molecule screening time from months to weeks while ensuring valuable intellectual property remains securely under company control. In January 2026, the partnership expanded with the announcement of a co-innovation AI lab, supported by an investment of more than $1 billion over 5 years.

How Can Organizations Manage Data Sensitivity Across the Drug Development Pipeline?

As potential drug candidates progress through the development pipeline, generated data becomes increasingly sensitive and subject to stricter regulatory oversight. Initial hit identification and lead optimization can leverage public cloud infrastructure for computational intensity, processing millions of molecular structures through docking algorithms and absorption, distribution, metabolism, excretion, and toxicity prediction models. As compounds advance to lead candidate selection, data transitions to private cloud or on-premises infrastructure, where tighter access controls and comprehensive audit trails support intellectual property protection and regulatory adherence.

This progressive security model aligns infrastructure controls with data sensitivity and regulatory requirements, optimizing both innovation velocity and adherence assurance throughout the discovery-to-development continuum.

How Does Hybrid Cloud Help Manage the Complexity of Global Clinical Trials?

Clinical trials represent one of the most heavily regulated and data-intensive phases of pharmaceutical development. The need to collaborate with research sites and partners globally while adhering to stringent patient privacy and data integrity standards makes hybrid cloud architectures indispensable. Modern electronic data capture systems increasingly leverage hybrid deployments, with patient-facing applications running in regional public cloud instances to minimize latency and address data sovereignty requirements, while master databases and analytics platforms reside in highly controlled private cloud or on-premises environments.

This distributed yet integrated architecture enables pharmaceutical companies to meet diverse regulatory requirements across jurisdictions while maintaining centralized data governance and quality control. Patient data can remain within required geographic boundaries while still enabling global study teams to access aggregated insights and conduct cross-site analyses.

How Does Hybrid Cloud Protect Patient Privacy?

Pharmaceutical companies increasingly augment traditional clinical trial data with real-world evidence from electronic health records, insurance claims databases, and patient registries to gain deeper insights into treatment efficacy and safety. Hybrid models facilitate this through federated learning, where analytical algorithms are sent to data locations—such as secure servers—allowing analysis without moving or exposing sensitive patient information.

This approach addresses the dual challenges of data privacy and data utility. Health care institutions maintain complete control over patient data within their secure environments, while pharmaceutical companies gain access to analytical insights that inform drug development, regulatory submissions, and postmarket surveillance strategies.

Machine learning models trained on historical trial data can identify optimal study sites, predict enrollment challenges, and recommend protocol amendments. These AI workloads benefit from cloud scalability during model training while maintaining regulatory-compliant deployment in controlled environments for production use. The hybrid model ensures training data—which may include sensitive historical patient information—never leaves the secure private environment, while enabling access to powerful computational resources needed for complex model development.

The digital transformation of pharmaceutical manufacturing, often referred to as Pharma 4.0, relies heavily on hybrid cloud capabilities. Process analytical technology initiatives involve continuous collection of sensor data from manufacturing equipment—bioreactors, chromatography systems, and analytical instruments. This data must be processed in real time to monitor and control manufacturing processes, while also being archived for long-term regulatory adherence under FDA and EMA regulations.

Hybrid architecture uniquely meets these diverse requirements through a tiered approach:

Table 1: Hybrid cloud infrastructure allocation for pharmaceutical manufacturing operations

How Does the Cloud Support Continuous Manufacturing Implementation?

Continuous manufacturing implementations particularly benefit from this tiered approach. Real-time process control systems that monitor critical quality attributes operate on dedicated on-premises infrastructure to ensure deterministic response times, essential for product quality and patient safety. Historical data flows to private cloud data lakes, where process engineers conduct statistical process control analysis, identifying trends and variations that inform process improvements. Public cloud resources manage computationally intensive process modeling and digital twin simulations that optimize yield, reduce waste, and accelerate process development.

This architecture enables pharmaceutical manufacturers to achieve the real-time responsiveness required for continuous operations while leveraging advanced analytics and modeling capabilities that drive operational excellence and regulatory adherence.

How Does Hybrid Cloud Enhance Global Supply Chain Management?

Commercial pharmaceutical operations increasingly depend on hybrid cloud infrastructure to manage the complexity of global supply chains. Demand forecasting models leverage public cloud elasticity to process point-of-sale data, wholesaler inventories, and prescription trends, enabling responsive production planning and inventory optimization. Manufacturing planning systems remain in controlled, private environments, where production schedules represent competitively sensitive information that requires protection from unauthorized access.

This segregation enables pharmaceutical companies to collaborate effectively with external partners and customers through cloud-based interfaces while protecting strategic operational information that provides a competitive advantage.

How Does Hybrid Cloud Support Track-and-Trace Adherence Across Global Supply Chains?

Track-and-trace implementations required by the Drug Supply Chain Security Act in the United States and the Falsified Medicines Directive in Europe benefit significantly from hybrid architectures. Product serialization data captured during manufacturing is stored in private cloud databases, ensuring security and control over production information. Verification transactions from distributors, pharmacies, and hospitals are processed through public cloud APIs that provide scalable global access while maintaining data sovereignty adherence across jurisdictions.

This hybrid model enables pharmaceutical companies to meet regulatory serialization requirements while supporting the global, distributed nature of pharmaceutical supply chains.

How Does Hybrid Cloud Streamline Regulatory Submissions?

Regulatory submissions represent the culmination of pharmaceutical development, demanding infrastructure supporting the creation, review, and submission of massive documentation packages. Hybrid cloud enables pharmaceutical companies to maintain submission content in highly controlled private cloud or on-premises environments where access controls, audit trails, and data integrity controls meet regulatory requirements. Cloud-based collaboration tools enable document authoring and review across geographically distributed teams, accelerating submission preparation while maintaining regulatory adherence.

This approach balances the need for secure, controlled document management with the collaborative requirements of modern pharmaceutical development, which involve global teams and external partners.

What Does a Graduated Approach to Hybrid Cloud Implementation Look Like?

Organizations achieving success with hybrid cloud architectures follow a graduated implementation approach. Initial pilots establish foundational capabilities, identity and access management, network connectivity, data classification frameworks, and basic workload deployment patterns. These pilots typically focus on lower-risk workloads that provide valuable learning while minimizing regulatory and operational risk.

As organizational expertise develops, companies scale production workloads, progressively moving more critical functions to hybrid architecture while continuously optimizing the balance between on-premises control and cloud agility. This graduated approach builds organizational capability, establishes governance frameworks, and demonstrates value before committing to large-scale transformation.

What Is Needed for Successful Hybrid Cloud Adoption?

Successful hybrid cloud adoption requires more than technology implementation—it demands the development of organizational capabilities and cultural transformation. IT teams must develop cloud architecture skills, automation capabilities, and DevOps practices. Quality and regulatory teams must understand cloud validation approaches and establish appropriate controls. Business stakeholders must engage in workload prioritization and risk-based decision-making about data placement and architecture choices.

Leading pharmaceutical organizations invest in training programs, establish centers of excellence, and create cross-functional teams that bring together IT, quality, regulatory, and business expertise to guide hybrid cloud strategy and implementation.

For the life sciences industry, hybrid cloud represents more than a technological choice—it is a strategic business enabler providing the flexible, scalable, and secure foundation required to navigate the complex landscape of modern pharmaceutical development and manufacturing. By strategically segmenting workloads and data based on computational needs, regulatory requirements, and intellectual property sensitivity, organizations accelerate innovation while upholding the highest standards of adherence and data integrity.

The ability to burst into public cloud for computationally intensive research while keeping clinical trial and manufacturing data in secure private environments allows pharmaceutical companies to optimize for both speed and control. As regulatory frameworks evolve, AI capabilities advance, and data volumes continue to grow exponentially, hybrid cloud architectures provide the flexibility pharmaceutical and biotechnology organizations require to innovate rapidly while maintaining the governance, adherence, and security needed to support their mission-critical work.

Organizations that thoughtfully align a hybrid cloud strategy with business objectives will capture substantial competitive advantages. The winning approach involves graduated sophistication: starting with focused pilots establishing foundational capabilities, scaling production workloads as expertise develops, and continuously optimizing the balance between on-premises control and cloud agility. Organizations that master hybrid deployment will lead the next decade of life sciences innovation and deliver transformative therapies to patients worldwide.

1. Precedence Research. Life science cloud computing market size, report by 2034. Precedence Research; 2025. Accessed March 23, 2026. 

https://www.precedenceresearch.com/life-science-cloud-computing-market

2. BioSpace. Life science cloud computing market accelerates as AI and digital transformation redefine infrastructure needs. BioSpace. Published November 30, 2025. 

https://www.biospace.com/press-releases/life-science-cloud-computing-market-accelerates

3. US Food and Drug Administration. Part 11, electronic records; electronic signatures — scope and application. FDA. Published August 24, 2018. 

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application

4. Google Cloud. GxP compliance. Accessed March 19, 2026. 

https://cloud.google.com/security/compliance/gxp

5. US Food and Drug Administration. Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products. Published January 6, 2025. 

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological

6. US Food and Drug Administration. Guiding principles of good AI practice in drug development. Published January 14, 2026. 

https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development

7. CNBC. Eli Lilly, Nvidia partner to build supercomputer, AI factory for drug discovery and development. Published October 28, 2025. 

https://www.cnbc.com/2025/10/28/eli-lilly-nvidia-supercomputer-ai-factory-drug-discovery.html

8. Fierce Biotech. Lilly, Nvidia tag on partnership with new AI co-innovation lab, $1B investment. Published January 12, 2026. 

https://www.fiercebiotech.com/biotech/lilly-nvidia-tag-partnership-new-ai-co-innovation-lab-1b-investment

9. Telekom Healthcare. The sovereign cloud offers more than just data privacy. Accessed March 19, 2026. 

https://www.telekom-healthcare.com/en/solutions/cloud-computing-healthcare/sovereign-cloud

10. US Food and Drug Administration. Guidance for Industry PAT — a framework for innovative pharmaceutical development, manufacturing, and quality assurance. Accessed March 19, 2026. 

Hybrid cloud architectures are becoming foundational in pharma and biotech by balancing public-cloud elasticity with private, single-tenant control needed for GxP, 21 CFR Part 11, and data sovereignty. Evolving FDA and joint FDA-EMA expectations for AI/ML—model governance, traceability, validation, and lifecycle management—further favor environments with strong visibility and auditability. Common deployment patterns include data-residency tiering, federated learning, and cloudbursting for compute peaks. Value is demonstrated across discovery, clinical trials, manufacturing (Pharma 4.0), supply chain, and regulatory submissions via a risk-based, graduated adoption model.

Hybrid cloud architecture enables pharma organizations to balance public cloud scalability with private infrastructure control, accelerating drug development while maintaining regulatory compliance.

Hybrid Cloud Architecture in Pharmaceutical Development and Manufacturing: A Strategic Imperative for Life Sciences

The views expressed in this article are attributed solely to the author and not to IBM.

	The pharmaceutical industry’s move from a blockbuster to a niched business model has resulted in overly complex portfolios, leading to inefficient use of resources and limiting companies’ ability to react quickly to changing market dynamics.

	Increasing complexity can be seen, not only at the level of materials, but throughout the enterprise.  For pharmaceutical companies, it generally shows up in manufacturing, supply-chain management, information and work flow, and quality functions. Its symptoms are summarized as follows:

		Frequent changeovers (small batches) to address unique product variations

		Complex manufacturing processes tailored to product specifications, especially for biologics; long and entangled global supply chains with each product having vastly different manufacturing trails/supplier networks 

		Manual processes for forecasting and allocating demand, for managing inventory, and for planning

		Limited master data management ability, leading to inability to capture material attributes, batch characteristics, and regulatory requirements within existing systems

		Lack of end-to-end visibility across the supply chain, making it difficult to make decisions.

		Difficulty maintaining batch genealogy and traceability

		Difficulty complying with country-specific regulatory requirements is getting difficult. 

	Traditional operational excellence approaches (e.g., Lean manufacturing or Six Sigma) can become untenable when the product stream is too complex. As a result, more pharmaceutical companies are examining their portfolios more closely to find ways to reduce complexity, and with it, waste, costs, and inventory levels. This article proposes the use of a comprehensive approach that targets both large and tail-end products for rationalization.

	Although complexity reduction (also referred to as stock keeping unit [SKU] rationalization or reduction, or product pooling) is widely used in industries such as consumer products and retail, it is a relatively new concept to the pharmaceutical industry.

	When complexity is managed effectively it turns into competitive advantage. Remember to do the following: 

		Look for areas of the business where complexity is driving excess cost, but not its fair share of value.Realize that complexity in and of itself is not a bad thing.

		Understand the true cost and value of complexity-this may require revisiting existing standard cost allocation to have transparency to the actual impact of complexity.

		Understand that complexity is an enterprise-wide issue, not a functional one-complexity is created through the way that we market, innovate, sell, procure, plan, and supply; cross-functional discussions are required to open up new levels of performance.

		Develop the rules and policies to guard against continued “entropy”-establish the structure, capability, governance, and way of working for the organization so that future decisions are made in line with the differentiation strategy.

		Re-architect the model to create transformational value-to create true competitive advantage, supply chains and assets should be tailored based on the “best fit” across product/service, market, and operations strategies.

	Beginning a complexity-reduction program requires focusing on the following specific areas. 

The first area to focus on in reducing complexity targets medium to large SKUs that do not directly satisfy a unique customer requirement. Removing redundant products offers significant cost savings, particularly for larger products that consume more resources.  Secondly, it has no impact on sales levels demand shifts to remaining products that still meet the customers’ requirement.

Removing smaller, less profitable products and product groups. 

Rationalizing products at the tail-end allows critical resources to be reallocated to more profitable products or new product launches. Some progressive pharma companies such as Novartis have piloted and partially implemented this approach with impressive results. Taking this step promises to improve demand forecast accuracy, production write-offs, asset utilization, and replenishment lead times.

Creating new products is not always the best way to achieve growth or profit, and often results in large, highly customized product portfolios and higher production, distribution, and other organizational costs. However, not all complexity is bad. When examining portfolios, it is important to distinguish between “value adding” and “value destroying” complexity. Research suggests using a “complexity fingerprint” (1) to identify specific areas of excess complexity. 

, is created by identifying the specific complexity drivers of a company-such as existing technologies, brands, products, and customers-and comparing this total number against the segment producing 80% of total earnings before interest and taxes (EBIT).

	A large gap, as illustrated by the large yellow area under the Products (SKUs) and customer drivers, between the total number and the segment producing 80% of total EBIT, suggests a need to reduce complexity.

	The complexity fingerprintenables transparency, catches management's attention, and leads to focusing and prioritizing problematic areas. For example, a manager in the company with this complexity fingerprint can easily see that packaging is an area of value-adding complexity, because 52% of packaging configurations account for 80% of packaging’s total contribution to overall EBIT. The manager can feel comfortable with the level of complexity in packaging. 

	However, this manager could examine the company’s customer base more critically, because only 10% of all customers contribute 80% of EBIT. Complexity reduction efforts could therefore focus on managing or pruning companies in the 90% of clients that contribute less than 20% of EBIT. 

Ensure that the right areas are targeted. 

When embarking on complexity reduction programs, there is always a risk of rationalizing in the wrong areas, cutting too deeply into revenue streams, discontinuing key products, or damaging important customer relationships. Companies can avoid this by conducting frequent product reviews with customers.

	In addition, it is important not to focus exclusively on removing tail-end SKUs, because this often results in insignificant changes in inventory, gross margins, market share, changeovers, or distribution complexity. Additionally, any cost savings resulting from tail-end product rationalization tends to be short-term because the tail-end of any portfolio always replaces itself over time.

Novartis, BMS, and other companies are reducing complexity by thinning out product portfolios. Reducing complexity can reduce waste and improve responsiveness, but it must be done right.